Antibacterial and Antibiofilm Efficacy of a Synthetic Nitrofuranyl Pyranopyrimidinone Derivative against Methicillin-Resistant Staphylococcus aureus
Abstract
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a major public health concern due to its multidrug resistance and robust biofilm formation, which contribute to persistent infections and treatment failures.Novel antibiofilm agents are urgently needed to combat drugresistant pathogens.This study evaluated the antibacterial and antibiofilm efficacy of NFPPO, a novel nitrofuranyl pyranopyrimidinone derivative, against preformed 1-, 3-, and 5-day-old MRSA biofilms.Methods: NFPPO was synthesized via a tandem Knoevenagel-Michael cyclocondensation reaction.The minimum inhibitory concentration (MIC) of NFPPO was determined against four clinical MRSA isolates and the reference strain S. aureus ATCC 700699.Antibiofilm activity was assessed against preformed 1-, 3-, and 5-day-old MRSA biofilms using the crystal violet assay.Confocal laser scanning microscopy (CLSM) quantified structural and viability changes in preformed biofilms post-NFPPO treatment.Results: All tested MRSA isolates and S. aureus ATCC 700699 exhibited vancomycin resistance (classified as VRSA), whereas NFPPO showed potent antibacterial activity (MIC, 8-16 µg/mL).All isolates formed robust biofilms (OD625 ≥ 3.0).Crystal violet assays and CLSM demonstrated significant NFPPO antibiofilm activity, reducing biofilm biomass and viability.Conclusions: NFPPO exhibited superior antibiofilm efficacy compared to vancomycin in eradicating in vitro preformed 1-, 3-, and 5-dayold MRSA biofilms.These findings…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.